Skip Navigation
Archive

NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.
​​
NIH HHS News Release Logo

National Institute of Allergy and
Infectious Diseases (NIAID)
http://www.niaid.nih.gov

FOR IMMEDIATE RELEASE
Thursday, April 11, 1996
5:00 p.m. Eastern Time

Media Contact:
Michael Miller (301) 496-1752
John Bowersox (301) 402-1663
niaidnews@niaid.nih.gov
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

AIDS Virus Reformatted to Shuttle Repair Genes to Diseased Brains

Scientists supported by the National Institutes of Health (NIH) have developed a benign, reconstituted form of HIV, the virus known to cause AIDS, and used it to shuttle repair genes to diseased neurons in rat brains. By removing any trace of the part of HIV that would allow it to replicate itself and become infectious (and thus lethal) and using only the part that can integrate itself into a host's gene sequence, the researchers were able to insert the reformatted HIV into non-dividing cells, specifically neurons, in the brains of rats.

Dr. Fred Gage, one of the three laboratory chiefs at the Salk Institute in La Jolla, Calif., where the discovery was made says, "The basic knowledge we have gleaned of how HIV infects cells has enabled us to develop a reconstituted HIV 'delivery system' for diseased neurons -- it is truly a case of turning swords into plowshares. Using a virus delivery system offers hope for successful gene therapy in many life-threatening diseases such as cystic fibrosis, muscular dystrophy and perhaps even Alzheimer's disease." The finding is reported in the April 12, 1996 issue of Science.

The ability to insert genetic material that may carry helpful information into genetic locations associated with diseases such as Parkinson's is a hallmark of gene therapy. This study is one of the first to show a workable model in animals that targets nerve cells. Gage's work was funded by the National Institute on Aging (NIA). His co-workers at the Salk Institute are Drs. Inder M. Verma and Didier Trono. Dr. Trono was funded by the National Institute of Allergy and Infectious Diseases (NIAID).

The initial breakthrough in this research came when Drs. Verma and Trono's labs extensively "debilitated" HIV and, using a protein piece from another virus, created very efficient viral vectors. Viral vectors are essentially microscopic shuttles which, by virtue of their stealth capabilities, carry genes to targeted cells. According to Dr. Trono, "The beauty of this vector is that healing genes can be delivered directly into the body, without cumbersome manipulations of the patients' cells in vitro. Genes can be introduced into targets such as neurons, which have previously been beyond the reach of many vectors. An additional benefit of this vector is that it does not trigger toxic immune reactions as other vectors have been known to do."

As proof of the effectiveness of Drs. Verma and Trono's vectors, Dr. Gage's lab introduced the recombinant HIV vectors into five female adult rat brains and showed that foreign genes carried by the shuttle vectors could be efficiently inserted into genes in a brain's neurons. The transferred product was detectable in the rat brains for at least a month.

Gage and his co-worker, Dr. Ulrike Blomer, who performed their work in live rats, suggest that if human testing is done, cow or monkey variants of HIV should be used to avoid any possibility of human infection with HIV. Gage says, "This science is a great example of melding two areas of basic research -- neurology and virology -- and using a substance like HIV to actually work to the good and not the ill."

The National Institute on Aging leads the federal effort supporting basic, clinical, epidemiological and behavioral research on aging and the special needs of older people. The National Institute of Allergy and Infectious Diseases conducts and supports research to prevent, diagnose and treat illnesses such as AIDS and other sexually transmitted diseases, tuberculosis, asthma and allergies. NIA and NIAID are both components of the National Institutes of Health, an agency of the U.S. Public Health Service, U.S. Department of Health and Human Services.


NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH...Turning Discovery Into Health ®

back to top


Archive

NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.
​​​​

Last Updated April 11, 1996